The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder

McIntyre, Roger S.; Woldeyohannes, Hanna O.; Soczynska, Joanna K.; Miranda, Andrew; Lachowski, A.; Liauw, Samantha S.; Grossman, Talia; Lourenço, Maria Helena; Kim, Byungsu; Alsuwaidan, Mohammad; Kennedy, Sidney H.

doi:10.1007/s12325-010-0072-z

Cited by 33 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comorbid metabolic disturbances in patients with BD have been associated with a more complex illness presentation, less favourable response to treatment, and worse course of illness (283,287,288).…”

Section: Prevalence and Impactmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

et al. 2012

View full text Add to dashboard Cite

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.  Bipolar Disord 2012: 00: 000–000. © 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd.The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first‐line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first‐line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first‐line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second‐line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not‐recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long‐acting injection, and adjunctive ziprasidone continue to be first‐line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third‐line options.

show abstract

Section: Prevalence and Impactmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Several studies have reported that metabolic syndrome tends to be associated with certain characteristics of bipolar disorder (Chang 2009;McIntyre 2010):…”

Section: Bipolar Disorder and Metabolic Syndromementioning

confidence: 99%

Metabolic syndrome in psychiatry: advances in understanding and management

Ho¹,

Zhang²,

Mak³

et al. 2014

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryMetabolic syndrome comprises a number of cardiovascular risk factors that increase morbidity and mortality. The increase in incidence of the syndrome among psychiatric patients has been unanimously demonstrated in recent studies and it has become one of the greatest challenges in psychiatric practice. Besides the use of psychotropic drugs, factors such as genetic polymorphisms, inflammation, endocrinopathies and unhealthy lifestyle contribute to the association between metabolic syndrome and a number of psychiatric disorders. In this article, we review the current diagnostic criteria for metabolic syndrome and propose clinically useful guidelines for psychiatrists to identify and monitor patients who may have the syndrome. We also outline the relationship between metabolic syndrome and individual psychiatric disorders, and discuss advances in pharmacological treatment for the syndrome, such as metformin.LEARNING OBJECTIVES•Be familiar with the definition of metabolic syndrome and its parameters of measurement.•Appreciate how individual psychiatric disorders contribute to metabolic syndrome and vice versa.•Develop a framework for the prevention, screening and management of metabolic syndrome in psychiatric patients.

show abstract

“…[455863] Some studies have found association between history of at least one suicide attempt and MetS,[43] others have reported no such association. [56] Similarly, comorbid substance use or smoking has been inconsistently associated with presence of MetS with some studies reporting higher prevalence of MetS in patients with comorbid substance use or smoking[9] and others have reported no such difference between those with MetS and those without MetS. [58] Studies have not found significant difference between patients with MetS and those without MetS with respect to presence of family history of lipid disorders or cardiovascular disease,[63] and rate of psychiatric comorbidity.…”

Section: Prevalence Of Components Of Metsmentioning

confidence: 99%

“…[58] Studies have not found significant difference between patients with MetS and those without MetS with respect to presence of family history of lipid disorders or cardiovascular disease,[63] and rate of psychiatric comorbidity. [56]…”

Section: Prevalence Of Components Of Metsmentioning

confidence: 99%

Metabolic Syndrome in Bipolar Disorders

Grover

Malhotra

Chakrabarti

et al. 2012

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

To review the data with respect to prevalence and risk factors of metabolic syndrome (MetS) in bipolar disorder patients. Electronic searches were done in PUBMED, Google Scholar and Science direct. From 2004 to June 2011, 34 articles were found which reported on the prevalence of MetS. The sample size of these studies varied from 15 to 822 patients, and the rates of MetS vary widely from 16.7% to 67% across different studies. None of the sociodemographic variable has emerged as a consistent risk factor for MetS. Among the clinical variables longer duration of illness, bipolar disorder- I, with greater number of lifetime depressive and manic episodes, and with more severe and difficult-to-treat index affective episode, with depression at onset and during acute episodes, lower in severity of mania during the index episode, later age of onset at first manic episode, later age at first treatment for the first treatment for both phases, less healthy diet as rated by patients themselves, absence of physical activity and family history of diabetes mellitus have been reported as clinical risk factors of MetS. Data suggests that metabolic syndrome is fairly prevalent in bipolar disorder patients.

show abstract

The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder

Cited by 33 publications

References 20 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

Metabolic syndrome in psychiatry: advances in understanding and management

Metabolic Syndrome in Bipolar Disorders

Contact Info

Product

Resources

About